3 recruiting, 3 terminated, 2 unknown, 1 not yet recruiting. 5 Phase 2, 4 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 2, Unknown 2, Recruiting 1 |
| Phase 1 | 4 | Terminated 3, Recruiting 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Relapsed or Refractory Acute Myeloid Leukemia (AML): new trials by email Literature Review of Relapsed or Refractory Acute Myeloid Leukemia (AML) trials Research Report on Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia PID23 Injection - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 18 | 2026-08-01 | 2026-07-10 |
| A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients Allogeneic Hematopoietic Stem Cell Transplantation - Relapsed or Refractory Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome) | Not applicable | Recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-04-01 | 2026-04-15 |
| BCL2i CLAG-M in R/R Acute Myeloid Leukemia Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 52 | 2024-11-26 | 2026-04-01 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Mitoxantrone Hydrochloride Liposome - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 | 2022-06-14 | 2024-02-23 |
| A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) HYML-122; cytarabine - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Unknown | Tarapeutics Science Inc. | 18 | 2022-03-29 | 2025-04-10 |
| A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) HYML-122 - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Unknown | Tarapeutics Science Inc. | 15 | 2021-09-29 | 2024-05-14 |
| An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) KRT-232, Cytarabine, Decitabine - Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN) | Phase 1 / Phase 2 | Terminated | Kartos Therapeutics, Inc. | 70 | 2019-09-25 | 2024-03-22 |
| Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. AZD5991, AZD5991 + Venetoclax - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Terminated | AstraZeneca | 70 | 2017-08-02 | 2022-09-23 |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation AG-120 - Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML | Phase 1 | Recruiting | Institut de Recherches Internationales Servier | 291 | 2014-03-01 | 2026-06-15 |
Leukemia, Myeloid, Acute (9) · Recurrence (9) · Anemia, Refractory, with Excess of Blasts (1) · Hematologic Neoplasms (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Disease Attributes (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Leukemia (9) · Leukemia, Myeloid (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Bone Marrow Diseases (2) · Anemia (1) · Anemia, Refractory (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1)
Cytarabine (3) · venetoclax (2) · AZD5991 (1) · Cladribine (1) · Clinical Protocols (1) · Decitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Mitoxantrone (1) · ivosidenib (1) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1)
Tarapeutics Science Inc. (2) · AstraZeneca (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Institut de Recherches Internationales Servier (1) · Kartos Therapeutics, Inc. (1) · The First Affiliated Hospital of Soochow University (1) · Zhujiang Hospital (1)
China (5) · United States (4) · France (2) · Australia (1) · Belgium (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Depei Wu, MD. PhD (2) · David Sallman, MD (1) · Depei Wu (1) · Xiaojin Wu (1)
PMID 27245312, PMID 29860938, PMID 30559424, PMID 31841594, PMID 32296873, PMID 32380538, PMID 33493392, PMID 37380821, PMID 38640348